Efficacy and Safety of Therapeutic Plasma Exchange vs Standard Medical Therapy in Severe Autoimmune Hepatitis.

Efficacy and Safety of Therapeutic Plasma Exchange vs Standard Medical Therapy in Severe Autoimmune Hepatitis: A Pilot Randomized Controlled Study

Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease that can lead to cirrhosis and liver failure. AIH can present in all ages, races, and ethnicities, but it mostly affects women. As a heterogeneous disease, AIH presents variably in different patients, making diagnosis and treatment a challenge.It is associated with varied clinical presentations and natural history and somewhat unpredictable treatment responses. Steroids and immunosupressants are main stay of treatment.In acute severe presentations corticosteroid response rates are more variable.According to treatment guidelines if patients fail to respond to corticosteroids, Liver transplant is the only option. But Liver transplant is not feasible in all situations such as limited donor availability.Plasma exchange is associated with a reduction in levels of pro-inflammatory cytokines,DAMPs, and bacterial endotoxins and increase in the levels of anti-inflammatory cytokines.Plasma exchange has reportedly been used for acute presentations of AIH but there are few trials which prove its independent benefit and role in influencing transplant free survival.The study aims at proving the efficacy of Plasma exchange as a bridge between steroid therapy and Liver transplant.It includes the patients with acute severe autoimmune hepatitis .One group of patients are taken up for plasma exchange sessions and compared with the other group started on high dose of steroids and they will be observed for 28 days and are assessed for transplant free survival and efficacy of plasma exchange in reducing transaminitis and Bilirubin levels.

Study Overview

• Status: Not yet recruiting
• Conditions: Autoimmune Hepatitis
• Intervention / Treatment: Biological: Plasma Exchange; Drug: Steroid; Dietary supplement: Diet

Detailed Description

• Study population: Patients presenting with severe autoimmune hepatitis and MELD>24 with no liver transplant option.
• Study design: A Pilot Randomised control trial
• Study period: 2 year
• Sample size:
• There is no studies of PE in severe AIH, assuming effect of PE in ACLF group
• Survival rate with plasma exchange was assumed to be 60 % and 20 % without PE.
• Further assuming 95% power and alpha 5 %.
• We need to enroll 46 cases i.e. 23 in each group
• Further assuming % defaulter rate, it is further decided to enroll 25 cases in each group.
• Patients will be randomly allocated in 2 groups by 1:1 block randomisation and will be implemented by IWRS facility taking block size 10.
• Monitoring and assessment: All patients would undergo vital and baseline parameter screening before randomization. Based on randomization they will receive either steroid or plasma exchange followed by steroid.
• Interim analysis would be done to check efficacy and safety of TPE in severe autoimmune hepatitis.
• Adverse effects:

Therapeutic Plasma Exchange is associated with risk of adverse events like infections,Fluid overload or circulatory insufficiency, Hypersensitivity to blood products.

- Stopping rule: Study will be stopped in case of life- threatening events occur in patient after randomisation

• Study Type: Interventional
• Enrollment (Estimated): 50
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Dr Satender Pal Singh, DM; Phone Number: 01146300000; Email: ama.satender@gmail.com
• Study Contact Backup: Name: Dr J.Gnana Kavitha, MD; Phone Number: 09717270640; Email: drkavitha777@gmail.com

Study Locations

• India
  • Delhi
    • New Delhi, Delhi, India, 110070
      • Institute of Liver & Biliary Sciences (ILBS)
      • Contact: Dr J.Gnana Kavitha, MD; Phone Number: 01146300000; Email: drkavitha777@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Age 18-60 years
2. Acute severe autoimmune hepatitis with MELD >24
3. No liver transplant option < 28 days.
4. -ACLF + Non ACLF
5. Auto immune hepatitis: Diagnosis by simplified AIH score ≥6

Exclusion Criteria:

1. Patients with Active sepsis
2. Patients with Active bleeding
3. Patients allergic to FFP and blood products
4. Patients with unstable hemodynamics ( eg:BP<90/60 mmhg,HR >100bpm)
5. Patients with post renal obstructive AKI, AKI suspected due to glomerulonephritis, interstitial nephritis or vasculitis based on clinical history and urine analysis
6. Pregnancy related liver failure
7. Comorbidities associated with poor outcome (Extrahepatic neoplasia, severe cardiopulmonary disease defined by a New York Heart Association score >3, or oxygen/steroid-dependent chronic obstructive pulmonary disease)
8. Refusal to participate in the study
9. Patients who are eligible to transplant
10. Patients who received steroids or on steroids last 7 days

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Plasma Exchange; 3 to 5 sessions +Steroids	Biological: Plasma Exchange; 3 to 5 sessions alternate day; Drug: Steroid; Steroid
Active Comparator: Standard Medical Treatment; Steroids + Nutrition	Drug: Steroid; Steroid; Dietary supplement: Diet; Diet

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Number of patients with change in AST,ALT,Bilirubin	28 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Liver transplant free survival at 28 days.		28 days
Development of adverse event due to TPE		28 days
Number of patients with development of clinical infection during study period	Clinical infections includes pneumonia, SBP,UTI,soft tissue infections,blood stream infections.	28 days
Mortality during hospital stay		28 days
Change in grade of HE, grade of ascites (both ascites and HE if present).		28 days
Frequency of decompensation events on follow up period.		28 days
Infections at 28 days		28 days

Collaborators and Investigators

• Sponsor: Institute of Liver and Biliary Sciences, India

Study record dates

Study Major Dates

• Study Start (Estimated): March 3, 2025
• Primary Completion (Estimated): February 28, 2027
• Study Completion (Estimated): February 28, 2027

Study Registration Dates

• First Submitted: February 17, 2025
• First Submitted That Met QC Criteria: March 3, 2025
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: March 3, 2025
• Last Verified: February 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Autoimmune Diseases; Immune System Diseases; Infections; RNA Virus Infections; Virus Diseases; Digestive System Diseases; Liver Diseases; Hepatitis, Viral, Human; Enterovirus Infections; Picornaviridae Infections; Hepatitis, Chronic; Hepatitis A; Hepatitis; Hepatitis, Autoimmune
• Other Study ID Numbers: ILBS-AIH-02

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No